Bavarian Nordic (BAVA) - Total Assets
Based on the latest financial reports, Bavarian Nordic (BAVA) holds total assets worth Dkr14.95 Billion DKK (≈ $2.34 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Bavarian Nordic cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Bavarian Nordic - Total Assets Trend (2000–2025)
This chart illustrates how Bavarian Nordic's total assets have evolved over time, based on quarterly financial data. See BAVA net asset value for net asset value and shareholders' equity analysis.
Bavarian Nordic - Asset Composition Analysis
Current Asset Composition (December 2025)
Bavarian Nordic's total assets of Dkr14.95 Billion consist of 45.1% current assets and 55.0% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 11.5% |
| Accounts Receivable | Dkr855.63 Million | 5.7% |
| Inventory | Dkr2.51 Billion | 16.8% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr5.96 Billion | 39.9% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Bavarian Nordic's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Bavarian Nordic worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bavarian Nordic's current assets represent 45.1% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 11.5% of total assets in 2025, down from 49.1% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 39.9% of total assets.
Bavarian Nordic Competitors by Total Assets
Key competitors of Bavarian Nordic based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Akero Therapeutics Inc
NASDAQ:AKRO
|
USA | $1.01 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Zealand Pharma A/S
CO:ZEAL
|
Denmark | Dkr16.46 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Immunitybio Inc
NASDAQ:IBRX
|
USA | $518.99 Million |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.66 Billion |
Bavarian Nordic - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.22 | 2.07 | 2.31 |
| Quick Ratio | 2.64 | 1.24 | 1.92 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr5.14 Billion | Dkr2.99 Billion | Dkr1.89 Billion |
Bavarian Nordic - Advanced Valuation Insights
This section examines the relationship between Bavarian Nordic's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 3.8% |
| Total Assets | Dkr14.95 Billion |
| Market Capitalization | $2.13 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bavarian Nordic's assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Bavarian Nordic's assets grew by 3.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Bavarian Nordic (2000–2025)
The table below shows the annual total assets of Bavarian Nordic from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Dkr14.95 Billion ≈ $2.34 Billion |
+3.81% |
| 2024-12-31 | Dkr14.41 Billion ≈ $2.25 Billion |
+0.37% |
| 2023-12-31 | Dkr14.35 Billion ≈ $2.25 Billion |
+15.83% |
| 2022-12-31 | Dkr12.39 Billion ≈ $1.94 Billion |
+2.50% |
| 2021-12-31 | Dkr12.09 Billion ≈ $1.89 Billion |
+38.02% |
| 2020-12-31 | Dkr8.76 Billion ≈ $1.37 Billion |
+24.29% |
| 2019-12-31 | Dkr7.05 Billion ≈ $1.10 Billion |
+130.23% |
| 2018-12-31 | Dkr3.06 Billion ≈ $478.91 Million |
-2.91% |
| 2017-12-31 | Dkr3.15 Billion ≈ $493.26 Million |
+11.65% |
| 2016-12-31 | Dkr2.82 Billion ≈ $441.79 Million |
+41.95% |
| 2015-12-31 | Dkr1.99 Billion ≈ $311.23 Million |
+5.40% |
| 2014-12-31 | Dkr1.89 Billion ≈ $295.28 Million |
+29.96% |
| 2013-12-31 | Dkr1.45 Billion ≈ $227.21 Million |
-5.65% |
| 2012-12-31 | Dkr1.54 Billion ≈ $240.82 Million |
-22.13% |
| 2011-12-31 | Dkr1.98 Billion ≈ $309.25 Million |
+34.72% |
| 2010-12-31 | Dkr1.47 Billion ≈ $229.54 Million |
+15.42% |
| 2009-12-31 | Dkr1.27 Billion ≈ $198.87 Million |
-24.98% |
| 2008-12-31 | Dkr1.69 Billion ≈ $265.08 Million |
-2.18% |
| 2007-12-31 | Dkr1.73 Billion ≈ $270.99 Million |
+81.48% |
| 2006-12-31 | Dkr954.42 Million ≈ $149.33 Million |
+2.78% |
| 2005-12-31 | Dkr928.56 Million ≈ $145.28 Million |
+54.22% |
| 2004-12-31 | Dkr602.10 Million ≈ $94.20 Million |
+40.29% |
| 2003-12-31 | Dkr429.17 Million ≈ $67.15 Million |
+35.09% |
| 2002-12-31 | Dkr317.70 Million ≈ $49.71 Million |
+413.46% |
| 2001-12-31 | Dkr61.87 Million ≈ $9.68 Million |
-26.07% |
| 2000-12-31 | Dkr83.69 Million ≈ $13.09 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more